In a new paper, researchers sought to describe how much the European Union is overspending on neovascular age-related macular degeneration treatment by relying on ranibizumab and aflibercept rather than bevacizumab in ophthalmology.
Bevacizumab represents an effective and relatively inexpensive anti—vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD), but because it is not approved for this indication, many physicians are discouraged from using bevacizumab to treat AMD. Even the United Kingdom’s National Institute for Health and Care Excellence (NICE) recommends using the more expensive anti-VEGF treatments ranibizumab or aflibercept to treat this disease.
In a new paper in PLOS One, researchers sought to describe how much the European Union is overspending on AMD treatment by relying on ranibizumab and aflibercept rather than bevacizumab in ophthalmology.
The researchers developed a patient-level decision analytic model to evaluate effectiveness, quality of life, and costs to compare ranibizumab used as needed and aflibercept administered bimonthly with bevacizumab used as needed. The model estimated the mean costs and benefits for a hypothetical group over a 1-year time horizon. To determine effectiveness of each drug, the researchers used a systematic review and meta-analysis of the literature. Costs were calculated from a societal perspective, including direct costs (including drug costs, medical visits, and examinations) and indirect costs (including the costs of low vision aids and nonmedical costs). They used a willingness-to-pay (WTP) threshold of €80,000 (approximately $93,325) per quality-adjusted life year (QALY). Overspending was defined as the amount of extra money paid for health care that cannot be justified by the WTP threshold of €80,000.
The researchers found:
They also compared aflibercept with bevacizumab to demonstrate what would be needed for it to be a justifiable alternative to bevacizumab, and found that aflibercept should be reduced from €943 (approximately $1100) to €533 (approximately $622) per injection. If aflibercept were to meet the WTP threshold practiced by NICE, it would have to be discounted to €447 (approximately $522) per injection. Alternatively, at its current price, aflibercept should provide at least an additional 0.041 QALYs per patient versus bevacizumab.
The United Kingdom alone, write the authors, is overspending by €52.5 million (approximately $60.6 million) annually. Europe as a whole could save €335 million (approximately $386 million) yearly by treating 80% of people with AMD with bevacizumab rather than aflibercept.
“The awareness of the importance of cost-effectiveness to keep health care sustainable is growing and new drugs should be critically appraised on their added value,” write the authors. “In the case of neovascular AMD treatment there is no question; bevacizumab is the most cost-effective anti-VEGF treatment for AMD.”
Reference
van Asten F, Michels CTJ, Hyong CB, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—a cost-effectiveness analysis from a societal perspective. [Published online May 17, 2018.] PLoS One. doi: 10.1371/journal.pone.0197670.
Ranibizumab Biosimilar Shows Reduced Efficacy vs Aflibercept in nAMD
April 3rd 2025The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related macular degeneration (nAMD), highlighting a potential trade-off between economic savings and clinical efficacy.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.